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ABSTRACT
Cell-free DNA (cfDNA) analysis may provide a non-invasive diagnostic approach for lung adenocarcinoma
patients. Recently, droplet digital PCR (ddPCR) has been developed as a highly sensitive detection method
for a low mutant allele percentage. The ddPCR detection limit for epithelial growth factor receptor (EGFR)
mutations was evaluated using cell lines, NCI-H1975 for EGFR L858R point mutation and PC-9 for EGFR
E746-A750del. Subsequently, detection of EGFR mutations by ddPCR was performed in tumor DNA (tDNA)
and cfDNA samples of 19 lung adenocarcinoma patients whose tumor biopsies were already evaluated for
EGFR mutations by clamp PCR (13 of L858R, 3 of E746-750del, and 3 of EGFR negative). In 12 cases,
immunohistochemical analysis was performed to quantify the number of EGFR L858R-positive cells rate.
EGFR point mutation or deletion were detected in 16 tumor DNA samples. In the measurable cfDNA sam-
ples, the rate of detection by ddPCR in cfDNA was 61.5% (8/13) for L858R and 100% (3/3) for E746-
A750del. A relative correlation was found between the allele fraction (AF) of tDNA and the number of EGFR
L858R-positive cells rate. No correlation was found between the AF of tDNA and AF of cfDNA. In our study,
cfDNA mutation detection was not associated with clinicopathological features, but cases with high AF of
cfDNA did have metastatic lesions. Our study shows that ddPCR enables cfDNA analysis for EGFR L858R
and E746-A750del, with a high detection rate. Therefore, cfDNA analysis using ddPCR may complement to
tumor biopsy and is beneficial for precision medicine in lung adenocarcinoma patients.
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INTRODUCTION
Cell-free DNAs (cfDNAs) derived from cancer cells
carry genetic information of cancer cells, including
tumor-specific mutations, from primary tumor and
metastasis sites3). These short double-stranded DNAs
circulating in the bloodstream are released from cancer
cells that undergo apoptotic and necrotic processes and
also from active cancer cells14). cfDNA has been proposed
as a minimally invasive tool for cancer diagnosis. Since it
is a blood-based biomaterial, it is termed as “liquid
biopsy”. Compared to the other biomaterial source for
liquid biopsy, cfDNA is relatively easy to be isolated.
However, because the fraction of cfDNA derived from
cancer cells is often low and it is short in length, a highly
sensitive mutation detection tool is required for cfDNA
analysis1,12).
The allele fraction (AF) in cfDNA may be correlated
with the detection limit of liquid biopsy. Droplet digital
PCR has recently emerged as a highly sensitive detection
tool for rare mutations and degraded DNA5). This study
evaluated the utility of droplet digital PCR for cfDNA
analysis and compared the results with those of tumor
samples to examine the detection limit of liquid biopsy
and its correlation with different grades of malignancy.
METHODS
Patients and Materials
Nineteen lung adenocarcinoma patients who were
treated at the Hiroshima University Hospital from 2010
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to 2017 were enrolled in this study. All patients had
undergone biopsy and were diagnosed with lung adeno-
carcinoma. EGFR gene status in the biopsy specimens
was evaluated by clamp PCR. Patient characteristics are
described in Table 1. The stages of cancer in patients
were determined based on the International Association
for the Study of Lung Cancer (IASLC) TNM staging sys-
tem 7th edition. Tumor DNA (tDNA) samples were iso-
lated from 19 formalin-fixed paraffin-embedded (FFPE)
samples obtained from primary or metastasis sites of
tumors. 14/19 samples were obtained by the transbron-
chial lung biopsy (TBLB) procedure and 5/19 samples
were obtained by surgical procedures. All biopsy samples
were obtained before the patients underwent chemother-
apy. Immunohistochemistry was performed in 12 FFPE
samples. cfDNA was isolated from 17 serum samples
taken at the time of diagnosis before starting chemother-
apy. The research workflow is illustrated in Figure 1.
Additionally, cfDNA isolated from 4 plasma samples of
healthy volunteers and placental DNA were used for set-
ting up detection limits of ddPCR assays. Moreover,
cfDNA of healthy volunteers was used to establish stand-
ards for false positive signals. The detection limit was
determined by the fractional abundance of the DNA of
the diluted cell line that was above the fractional abun-
dance of cfDNA of healthy volunteers; placental DNA
was used as a negative control. For ddPCR, DNA isolated
from NCI-H1975 and PC-9 cell lines were used as posi-
tive controls for L858R and E746-A750del, respectively,
and DNA isolated from Lc-Ad1 cell line was used as a
negative control. For immunohistochemical studies,
NCI-H1975 and Lc-Ad1 cell lines were used as positive
and negative controls, respectively.
DNA Isolation
cfDNA was isolated from 1.5 ml of serum and 1 ml
plasma using Circulating Nucleic Acid kit (Qiagen, Hil-
den, Germany) following the manufacturer’s instruc-
tions. Genomic DNA was extracted from FFPE samples
using QIAamp DNA FFPE Tissue kit (Qiagen, Hilden,
Germany). DNA from cell lines was isolated using
QIAamp DNA Micro Kit (Qiagen, Hilden, Germany)
Table 1 Patient Characteristics (N = 19).


















1 62 M 1b 2 1 4 Primary site TBLB L858R 16.1 5.12 3.4
2 65 M 4 1 1 4 Primary site TBLB L858R 52.6 4.21 32.1
3 78 F 2a 1 1 4 Primary site TBLB L858R 5.68 0.55 21.2
4 73 M 1a 3 1 4 Metastasis site TBLB L858R 33.3 0.21 93
5 85 F 1b 3 1 4 Primary site TBLB L858R 15 0.09 19.1
6 71 F 2a 3 1 4 Primary site TBLB L858R 8.32 0.08 18.9
7 80 M 2a 0 1 4 Primary site Surgical L858R 51 0.05 50.2
8 72 F 2a 0 0 1B Primary site Surgical L858R 29.8 0.04 73.2
9 75 F 2b 2 1 4 Primary site TBLB L858R 42.8 0 67.7
10 77 M 4 0 1 4 Primary site TBLB L858R 71 0 52.1
11 87 F 2a 3 0 3B Primary site TBLB L858R 34.3 0 N/A
12 69 M 1a 3 1 4 Metastasis site Surgical E746-A750del 16.1 18.60 N/A
13 62 F 2a 3 1 4 Primary site TBLB E746-A750del 34.7 0.15 N/A
14 57 F 4 3 1 4 Primary site TBLB E746-A750del 7.45 0.07 N/A
15 66 F 4 3 1 4 Primary site TBLB Negative 0 0 N/A
16 72 M 2a 0 0 1B Primary site Surgical Negative 0 0 N/A
17 67 M 3 3 1 4 Primary site TBLB Negative 0 0 N/A
18 80 F 2a 0 0 1B Primary site TBLB L858R 11.8 N/A 15.2
19 81 M 2a 0 0 1B Primary site Surgical L858R 5.7 N/A 33.6
N/A: not available; Stage: According to International Association for the Study of Lung Cancer (IASLC) TNM staging system 7th
edition, AF: allele fraction; tDNA: tumor DNA; cfDNA: cell-free DNA, TBLB: transbronchial lung biopsy.
Figure 1 Research workflow. cfDNA: cell-free DNA, ddPCR: droplet digital PCR, FFPE: formalin-fixed paraffin-embedded.
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according to the manufacturer’s instructions. All DNA
quantification was performed using Qubit 2.0 fluorome-
ter (Thermo Fisher, Waltham, MA, USA) and the iso-
lated DNA samples were stored at 4°C until use.
Droplet Digital PCR
Allele fractions (AFs) were measured using the QX100
Droplet Digital PCR System (Bio-Rad, Hercules, CA,
USA). Commercially available EGFR L858R point muta-
tion and E746-A750del detection assays were used (Bio-
Rad, Hercules, CA, USA). The ddPCR reaction sample
contained a final reaction volume of 22 μL consisting of
approximately 30 ng cfDNA or 10 ng tDNA, 10 μL 2X
ddPCR supermix for probes (No dUTP), 1 μL EFGR
assay FAM-labeled primer-probe for the mutated allele,
1 μL EGFR assay HEX-labeled primer-probe for wild
type allele, and nuclease-free water. The QX100 droplet
generator partitioned the samples into approximately
20,000 uniform droplets per sample. Later, 40 μL of
ddPCR reaction mixtures were run in a 96-well plate on
the ProFlex PCR system (Life Technologies, Carlsbad,
CA, USA) using previously described PCR conditions8).
Data were analyzed using QuantaSoft v1.3.2.0 Software
(Bio-Rad, Hercules, CA, USA). ddPCR of serial dilutions
of NCI H1975 and PC9 cell lines DNA with wild-type
human genomic DNA was performed to determine the
detection limit of ddPCR assays.
Immunohistochemical analysis
Immunohistochemistry was performed on 5-μm-thick
sections cut from FFPE samples using EGF receptor
L858R mutant-specific rabbit monoclonal antibody (Cell
Signaling Technology, Danvers, MA, USA). EGFR
L858R-positive cell rate was calculated based on the
number of stained cells compared to the total number of
cells, both EGFR L858R-positive and -negative, observed
under a microscope at 20x magnification. The micro-
scopic fields in which the cells were counted were ran-
domly selected. These cells were manually counted and
supported by ImageJ software (NIH and LOCI, WI,
USA).
Statistical Analysis
Statistical analyses were performed using Fisher’s
exact test or Spearman’s correlation coefficient where
appropriate. P values < 0.05 were considered to be statis-
tically significant. Statistical analysis was performed
using SPSS statistics version 22 (IBM SPSS Statistics,
Armonk, NY, USA).
Ethical Approval
This study was approved by the Institutional Review
Boards at Hiroshima University Hospital (IRB 326). All
patients provided written informed consent.
RESULTS
Detection Limit of ddPCR Assays
The mutant AFs of NCI-H1975 and PC-9 cell lines
DNA analyzed by ddPCR were 65% and 87%, respec-
tively. The result of a series of dilutions of the cell lines
DNA showed good correlation with the result of frac-
tional abundance obtained by ddPCR. Based on the ser-
ies of cell line dilution analysis, EGFR mutation assays
enabled detection of mutations at a limit of AFs of
0.024% for the L858R point mutation assay and 0.003%
for the E746-A750del assay (Figure 2).
Evaluation of AFs of cfDNA and tDNA
In tDNA samples, EGFR L858R point mutation was
detected in all the 13 samples and EGFR E746-A750del
was detected in 3 samples. In cfDNA samples, EGFR
L858R point mutation was detected in 8 out of 13
(61.5%) cases and EGFR E746-A750del was detected in
3 out of 3 (100%) samples. Among the cases in which
mutations were detectable, AFs of EGFR L858R point
mutation in cfDNA samples ranged from 0.04% to 5.12%
(mean 1.3%), and in EGFR E746-A750del they ranged
from 0.07% to 18.6% (mean 6.3%). Compared to cfDNA,
AFs in tDNA were high, ranging from 5.7% to 71%
(mean 32.7%) for EGFR L858R and from 7.5% to 34.7%
(mean 19.4%) for EGFR E746-A750del. However, EGFR
L858R point mutation was undetectable in cfDNA sam-
ples in three L858R-mutated cases.
Figure 2 Detection limit of ddPCR assays indicated as the lowest fractional abundance of diluted cell lines above the fractional
abundance of plasma of healthy volunteers. A. Detection limit for EGFR L858R point mutation assay using serial dilutions of DNA
from NCI-H1975 cell line is 0.024%. B. Detection limit for EGFR E746-750 deletion assay using serial dilutions of DNA PC-9 cell
lines is 0.003%. WT: plasma of healthy volunteers, Arrow: the detection limit of the mutation and deletion.
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Correlation of AFs in cfDNA and tDNA and
Mutated Cell Rate
The average mutation-positive cells detected in surgi-
cally resected samples and from TBLB samples were
52.3% and 35.9%, respectively. The AFs of tDNA by
ddPCR was relatively correlated with the percentage of
mutated cells in the tumor section (r = 0.53, p = 0.1, N =
12) (Figure 3). However, no correlation was observed
between AFs of cfDNA and those of tDNA (r = –0.11, p =
0.69, N = 17) (Figure 4). Similarly, correlation was not
found between AFs of cfDNA and mutation-positive cell
rate (r = –0.56, p = 0.09, N = 10).
Association of EGFR Mutations with
Clinicopathological Status and Clinical Features
Comparison between the EGFR L858R mutation AF
rate in cfDNA and the EGFR L858R-positive cell rate of
Figure 3 Correlation of EGFR L858R-positive cell rate and
AF of mutations in tDNA (N = 12, r = 0.53, p = 0.1). AF: allele
fraction.
Figure 4 Correlation of AFs of mutations in tDNA and in
cfDNA. There is no significant correlation. (N = 17, r = –0.11,
p = 0.69). ○: EGFR L858R point mutated cases, △: EGFR
E746-750 deleted cases, ●: wildtype cases, AF: allele fraction,
cfDNA: cell-free DNA, tDNA: tumor DNA.
tumor biopsy from the primary site, obtained by TBLB
procedure, was performed. Surprisingly, the sample with
the lowest number of EGFR L858R-positive cell rate has
the highest AF of cfDNA (5.12%) (Case 1). In contrast,
the mutated allele was not detectable in cfDNA sample
derived from the patient with the highest number of
EGFR L858R-positive cell rate (Case 9) (Figure 5).
Therefore, the AF rates were not considered to reflect the
rates of mutated tumor cells in primary tumors.
In the patients with and without detectable mutation
in cfDNA, association analyses with the clinicopathologi-
cal status and clinical features, including outcome, tumor
size, lymph node metastasis, distant metastasis, and
stage of cancer, were conducted. However, there was no
statistically significant difference observed between the
tumor characteristics and the clinical parameters. Subse-
quently, AFs of cfDNA were divided into two groups,
≤ 0.1% and > 0.1%, and association analyses were per-
formed. There was no difference in clinical and tumor
characteristics between groups with AFs of cfDNA
≤ 0.1% and > 0.1%. Interestingly, all patients with AFs of
cfDNA > 0.1% had lymph node metastasis and distant
metastasis (Table 2).
DISCUSSION
cfDNA derived from tumor cells is diluted with an
abundant amount of cfDNA derived from normal cells.
Moreover, cfDNA is usually degraded to several hun-
dreds of base pairs. Thus, the fraction of a particular
mutant allele is likely to be very low in a of cfDNA13). In
this study, we showed the ability of ddPCR to detect low
levels AFs in cfDNA, as low as 0.04%. Furthermore, our
result demonstrated a high detection rate for EGFR
mutations in cfDNA by ddPCR. Compared to an alterna-
tive cfDNA detection platform, we present ddPCR as a
highly sensitive detection method3). A previous study
that used ddPCR to evaluate EGFR mutation in cfDNA
showed a high detection rate using this method (95%)11).
Based on these results, we suggest that cfDNA analysis
offers a complementary detection assay and is beneficial
for patients from whom only a limited amount of tumor
biopsy sample can be obtained.
In this study, we evaluated mutated cell fractions in
tumors using an EGFR L858R mutant-specific antibody.
The EGFR L858R-mutated cell rate relatively correlated
with AF of tDNA; however, there was no correlation
between the AFs in cfDNA and tDNA. Since cfDNA is
usually considered to be derived from tumor cells as well
as normal cells, the mutant AF is consequently lower in
cfDNA and tDNA. Interestingly, our data showed that
the highest AF detected in cfDNA had the smallest tumor
cellularity based on immunohistochemical studies. Pre-
vious studies comparing the detection of specific genes
also showed discordance between tDNA and cfDNA2,4).
Instead of mutated cell numbers, we suggest that AFs of
cfDNA may be associated with the characteristics of the
tumor, such as grades of malignancy, or vascular inva-
sion, or lymph node metastasis and distant metastasis.
In fact, all the cases in which mutated AFs of cfDNA were
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> 0.1% were found to be metastatic cases.
The presence of mutations of cfDNA in the blood has
been correlated with overall survival, progression-free
survival, response to therapy, disease progression, and
poorer prognosis in previous studies6,15). In addition, lev-
els of cfDNA mutations have been correlated with tumor
volumes9) and were demonstrated to be remarkably
higher in patients with detectable cfDNA mutations10).
On the contrary, another study did not find a correlation
between mutations found in cfDNA with tumor sizes7). In
the present study, a comparison of detectability of cfDNA
mutations and clinicopathological status and clinical fea-
tures, including tumor size and patient outcome,
revealed that there were no differences between patients
with and without detectably mutated cfDNA. Similarly,
clinical and tumor characteristics did not differ between
groups of patients with high or low mutant AFs of
cfDNA. However, we noted that a high number of
patients with mutated cfDNA had lymph node metasta-
sis, distant metastasis, and advanced stage of cancer. A
similar pattern was observed in the group of patients
with AF of cfDNA > 0.1%. In this group, all patients had
lymph node metastasis and distant metastasis. These
findings strengthen our suggestion that AF of cfDNA
may be closely associated with lymph node and distant
metastasis.
In conclusion, ddPCR is a promising technique with
high detection rate for the molecular analysis of EGFR
mutations in cfDNA of lung adenocarcinoma patients.
Moreover, patients having limited tumor cell numbers in
their biopsy samples could benefit from cfDNA mutation
analysis.
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